Fennec Pharmaceuticals Inc. (FENC) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
FENC Revenue Growth
Revenue Breakdown (FY 2020)
FENC's revenue distribution by segment and geography for fiscal year 2020
By Product/Segment
FENC Revenue Analysis (2013–2024)
As of May 8, 2026, Fennec Pharmaceuticals Inc. (FENC) generated trailing twelve-month (TTM) revenue of $38.8 million, reflecting explosive growth of +78.7% year-over-year. The most recent quarter (Q3 2025) recorded $12.5 million in revenue, up 29.1% sequentially.
Looking at the longer-term picture, FENC's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $47.5 million in 2024, representing a new all-time high.
Revenue diversification analysis shows FENC's business is primarily driven by Royalty (100%). With over half of revenue concentrated in Royalty, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including LCTX (+53.2% YoY), SNOA (+26.8% YoY), and HALO (+37.6% YoY), FENC has outperformed the peer group in terms of revenue growth. Compare FENC vs LCTX →
FENC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FENCCurrent | $39M | +78.7% | - | 5.4% | |
 LCTX | $15M | +53.2% | +79.9% | -251.6% | |
 SNOA | $14M | +26.8% | -4.4% | -26.0% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% |
FENC Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $47.5M | +123.7% | $44.4M | 93.3% | $2.6M | 5.4% |
| 2023 | $21.3M | +1341.6% | $20.0M | 94.1% | $-12,771,000 | -60.1% |
| 2022 | $1.5M | - | $1.4M | 94.4% | $-21,693,963 | -1471.6% |
| 2021 | $0 | -100.0% | $0 | - | $-17,071,455 | - |
| 2020 | $170K | - | $170K | 100.0% | $-17,885,000 | -10520.6% |
| 2019 | $0 | - | $0 | - | $-13,311,439 | - |
| 2018 | $0 | - | $0 | - | $-10,409,000 | - |
| 2017 | $0 | - | $0 | - | $-6,951,000 | - |
| 2016 | $0 | - | $0 | - | $-2,871,000 | - |
| 2015 | $0 | - | $0 | - | $-1,890,000 | - |
See FENC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FENC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FENC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFENC — Frequently Asked Questions
Quick answers to the most common questions about buying FENC stock.
Is FENC's revenue growth accelerating or slowing?
FENC revenue is accelerating at +78.7% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $39M. Growth momentum has increased versus prior periods.
What is FENC's long-term revenue growth rate?
Fennec Pharmaceuticals Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +78.7% is above this long-term average.
How is FENC's revenue distributed by segment?
FENC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.